Biotech Values

[vinmantoo]

pcrutch,

<SubQ Velcade has drastic reductions in PN and other AEs, so Onyx claim doesnt seem all that strong. I wasn't making any claim about the cardiac related AEs, which Onyx seems to have plenty of as well.>


I see there is a reduction with sc Velcade, but there is still some significant grade 3/4 toxicities. As far as Carfilzomib, heart toxicity was something I hadn't heard might be an issue before today.



""Grade 3 and above adverse events with differences greater than 5 percent between routes of administration were:

• Peripheral neuropathy, subcutaneous 6 percent, intravenous 16 percent
• Thrombocytopenia, subcutaneous 13 percent, intravenous 19 percent
• Neuralgia, subcutaneous 3 percent, intravenous 9 percent""